When Novo Nordisk filed suit against Hims & Hers in early February, the case immediately drew attention as a high-stakes patent fight over semaglutide and what it could mean for the broader multi-billion-dollar market for GLP-1 treatments. In its headline-making complaint, Novo alleges that Hims\u2019 compounded weight-loss products infringe one of its U.S. utility patents, which covers the semaglutide compound in Novo\u2019s Ozempic, Wegovy, and Rybelsus drugs.<\/p>\n
At first glance, the dispute looks like a straightforward patent enforcement action. But a more recently filed consumer class action\u00a0adds a parallel set of allegations\u00a0to the litigation landscape, reframing the conflict as one that spans patent law, FDA regulation, pharmaceutical manufacturing, and brand positioning<\/a> in a market that is both commercially dominant and culturally ubiquitous<\/a>.<\/p>\n Taken together, the lawsuits reveal how complex \u2013 and consequential \u2013 the modern GLP-1 market has become.<\/p>\n Novo Nordisk v. Hims & Hers<\/p>\n Filed in the U.S. District Court for the District of Delaware on February 9, Novo\u2019s lawsuit <\/a>against NYSE-traded Hims & Hers Health, Inc. centers on Novo\u2019s U.S. Patent No. 8,129,343, which covers the semaglutide compound itself, pharmaceutical compositions containing it, and methods of treatment using those compositions. Novo alleges that Hims is marketing and selling compounded semaglutide injections and oral products containing its patent-protected molecule without authorization.<\/p>\n Shortly before Novo filed suit, Hims announced a $49 compounded oral semaglutide pill as an alternative to Novo\u2019s newly launched oral Wegovy, which carries a starting price of $149 per month. It withdrew the pill within days after Novo objected and federal regulators warned that certain compounded semaglutide products could be unlawful.<\/p>\n In a February 9 press release announcing its lawsuit, Novo cited the short-lived pill as an example of what it described as unlawful mass compounding that infringed the \u2019343 patent.\u00a0In its suit, the Danish pharmaceutical giant further maintains that it does not supply its semaglutide active pharmaceutical ingredient to compounders and that no generic version has received FDA approval. So, if Hims\u2019 products contain semaglutide as claimed in the \u2019343 patent, Novo argues, they are infringing its rights.<\/p>\n Hims said in a statement that the lawsuit is \u201ca blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care\u201d and is another case of Big Pharma \u201cweaponizing the US judicial system to limit consumer choice.\u201c<\/p>\n But that is only one dimension of the dispute.<\/p>\n A Second Lawsuit Complicates the Narrative<\/p>\n In the wake of Novo filing suit against Hims, consumer plaintiffs Andrew Donoho and Gloria Ferguson brought a separate case<\/a> in an Illinois federal court alleging that Hims has misled purchasers by advertising its \u201ccompounded semaglutide\u201d as having \u201cthe same active ingredient as Ozempic and Wegovy.\u201d Unlike Novo\u2019s patent case, the Illinois complaint does not hinge on whether Hims\u2019 product contains semaglutide. Instead, it asks whether marketing the compounded drug<\/a> as having the \u201csame active ingredient\u201d as Ozempic and Wegovy overstates the similarity between them.<\/p>\n Donoho and Ferguson argue that Hims\u2019 pattern of describing the compounded product as having the \u201csame active ingredient\u201d as Novo\u2019s drugs is misleading because, although both products contain semaglutide, Hims\u2019 synthetic manufacturing process allegedly produces a materially different active ingredient with additional peptide impurities, rendering the \u201csame active ingredient\u201d claim false and misleading.<\/p>\n With that in mind, Donoho and Ferguson\u2019s case \u2013 which primarily sets out claims under Illinois\u2019 Consumer Fraud and Deceptive Trade Practices Act \u2013 focuses on how Hims presents its compounded product to consumers, whereas Novo\u2019s lawsuit centers on whether that product contains the patented molecule at all.\u00a0<\/p>\n Where the Cases Converge<\/p>\n Viewed together, the two lawsuits expose an interesting tension. Novo alleges that because Hims\u2019 compounded products contain semaglutide claimed in the \u2019343 patent, their sale infringes its patent rights. The Illinois plaintiffs, by contrast, argue that Hims\u2019 products are different enough that describing them as having the \u201csame active ingredient\u201d misleads consumers.<\/p>\n That paradox \u2013 similarity for purposes of infringement, difference for purposes of advertising \u2013 sits at the center of the dispute. A product can, in theory, be sufficiently aligned with a patented compound to trigger liability, yet sufficiently distinct in formulation or regulatory status that claims of equivalence invite scrutiny. The GLP-1 market brings those two propositions into particularly sharp tension.<\/p>\n The cases also make clear that what is being protected \u2013 and potentially infringed \u2013 here goes beyond pure chemistry. Novo\u2019s complaint is framed as a patent action, but it also reinforces the regulatory pedigree and position of Ozempic and Wegovy, brands that now carry enormous commercial weight. The Illinois plaintiffs\u2019 theory similarly turns on the power of those names, alleging that repeated references to them help align Hims\u2019 compounded offerings with Novo\u2019s FDA-approved drugs.<\/p>\n Novo\u2019s lawsuit also fits within a broader pattern of enforcement. The company has filed a growing list of trademark actions<\/a> against parties that use its trademarks, \u201cOzempic\u201d included, to describe compounded products not made by Novo, arguing that such references risk confusing consumers and blurring the distinction between FDA-approved drugs and compounded alternatives. Those actions underscore that Novo is not only protecting a molecule, but policing how its brand names are used in the marketplace.<\/p>\n